EPS for Galmed Pharmaceuticals Ltd. (GLMD) Expected At $-0.14

October 14, 2018 - By Ellis Scott

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Logo

Analysts expect Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) to report $-0.14 EPS on November, 8.They anticipate $0.09 EPS change or 39.13 % from last quarter’s $-0.23 EPS. After having $-0.17 EPS previously, Galmed Pharmaceuticals Ltd.’s analysts see -17.65 % EPS growth. The stock increased 2.37% or $0.27 during the last trading session, reaching $11.64. About 135,646 shares traded. Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has risen 63.87% since October 14, 2017 and is uptrending. It has outperformed by 48.25% the S&P500.

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Ratings Coverage

Among 4 analysts covering Galmed Pharmaceuticals (NASDAQ:GLMD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Galmed Pharmaceuticals had 4 analyst reports since June 13, 2018 according to SRatingsIntel. The company was maintained on Wednesday, June 13 by Maxim Group.

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company has market cap of $243.44 million. The firm is developing Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It currently has negative earnings. It is also evaluating Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.

More recent Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) news were published by: Investorplace.com which released: “10 Killer Stocks to Buy That No One Knows About” on October 12, 2018. Also Streetinsider.com published the news titled: “Galmed Pharma (GLMD) Announces Late-Breaking Abstract on Aramchol to be Presented at AASLD” on October 02, 2018. Seekingalpha.com‘s news article titled: “Expected Value Investing: The Case Against Galmed” with publication date: October 05, 2018 was also an interesting one.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>